The SEC said today that Clovis Oncology (NSDQ:CLVS), its CEO and former CFO will pay more than $20 million to settle charges that the company misled investors about its experimental lung cancer drug. The SEC alleged that beginning in July 2015 and over the course of a four-month period, CEO Patrick Mahaffy and his team at Clovis […]
FDA clears Olympus’ latest biopsy needle
Olympus said it has won FDA clearance for its EZ Shot Plus 25 G needle as well as an expanded indication for the EZ Shot 3 Plus product line for both fine needle aspiration (FNA) and fine needle biopsy (FNB). The approvals “can drive improved staging of disease and the potential to more easily connect patients […]
Hackers steal patient info from Guardant Health
Liquid biopsy company Guardant Health has revealed that 1,100 patients’ information was stolen in a phishing attack in July. The Redwood City, Calif. company said in an SEC filing that an unauthorized user hacked an employee’s email account and accessed patients’ names, contact information, birth dates, medical diagnosis codes, and, in a very limited number […]
AngioDynamics to acquire radiation dose tech dev RadiaDyne
AngioDynamics (NSDQ:ANGO) said today that it inked a deal to acquire dose monitoring tech developer RadiaDyne for an undisclosed amount. The deal will add RadiaDyne’s early-stage OARtrac real-time radiation dose monitoring platform and its IsoLoc, ImmobiLoc and Alatus balloon stabilizing technologies to Latham, N.Y.-based AngioDynamic’s oncology portfolio, the company said. “The acquisition of RadiaDyne, combined with […]
Novocure inks Chinese collaborative dev, commercialization deal with Zai Lab
Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. Read the whole story on […]
Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival. Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a […]
Cook, AcuityBio ink deal for lung cancer drug technology
Cook Biotech will collaborate with drug-delivery maker AcuityBio on Acuity’s lead lung cancer product, the companies said today. Acuity’s ABC103 will use Cook Biotech’s proprietary extracellular matrix (ECM) technology. ABC103 is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/ cleared surgical staple-line buttress, drug-eluting polymers and […]
Body Vision raises $8.5 million to market cancer diagnostic system in U.S.
Body Vision Medical said today it has landed $8.5 million in funding to accelerate the commercialization of its LungVision lung navigation system in the U.S. and to extend its product line. The Ramat Ha Sharon, Israel-based company specializes in lung cancer diagnostics through augmented real-time intra-body navigation and imaging. Its catheter is designed for use […]
Check-Cap touts interim post-CE Mark C-Scan study results
Check-Cap (NSDQ:CHEK) today released interim results from the post-CE Mark approval study of its C-Scan system version 3, touting the device’s ability to detect polyps in un-prepped colons. The Israel-based company’s C-Scan system is designed as an alternative to standard colon cancer screening methods. The system uses an ingestible, ultra-low dose X-ray capsule and a wireless […]
Tracking tumors with Precipio’s liquid biopsy tech
In the era of personalized medicine, cancer patients will often have their tumors biopsied and analyzed as doctors hunt for mutations that are driving the patient’s condition. For some forms of cancer, doctors can recommend therapies that target particular genetic changes. “The problem is – and this is why cancer is such a tough disease […]
Alpha Tau wins approval to test cancer-targeting device in the U.S.
Alpha Tau Medical can begin U.S. clinical trials of its cancer-zapping device, thanks to a new permit from the Massachusetts Radiation Control Program. The state agency granted a Sealed Source and Device (SSD) approval to the Tel Aviv company’s Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy), which enables alpha-radiation-based cancer treatment for various types of solid […]
- 1
- 2
- 3
- …
- 70
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+